OPAN-OTOL-MSOIA-BGMisms: The capsular group B meningococcal vaccine (4CMenB) vaccine has been known to have postimmunisation fever rates of approximately 61%.

Thursday, 21 September 2017

The capsular group B meningococcal vaccine (4CMenB) vaccine has been known to have postimmunisation fever rates of approximately 61%.

The capsular group B meningococcal vaccine (4CMenB) vaccine has been known to have postimmunisation fever rates of approximately 61%.

No comments:

Subscribe to: Post Comments (Atom)